mTOR Signaling Pathway in Antiphospholipid Syndrome: Pathogenesis and Potential Therapeutic Targets

Area of Science:

• Immunology
• Pathology
• Pharmacology

Background:

• Antiphospholipid syndrome (APS) is an autoimmune disorder causing thrombosis and obstetric complications (OAPS).
• Current understanding suggests APS pathogenesis involves activated vascular endothelial cells, immune cells, and complement.
• Further research is needed to elucidate the precise mechanisms underlying APS.

Purpose of the Study:

• To explore the potential pathogenic role of the mammalian target of rapamycin (mTOR) signaling pathway in Antiphospholipid syndrome (APS).
• To investigate how mTOR activation may mediate immune disorders leading to thrombosis and OAPS.
• To identify new therapeutic targets for APS management.

Main Methods:

• Literature review and synthesis of existing research on mTOR signaling and APS.
• Analysis of proposed mechanisms linking mTOR activation to pro-inflammatory and pro-coagulant processes.
• Exploration of the intermediate role of mTOR in immune dysregulation in APS.

Main Results:

• Previous studies indicate mTOR is associated with pro-inflammatory and pro-coagulant processes.
• The mTOR signaling pathway activation may act as an intermediate mediator in APS pathogenesis.
• This pathway activation could link immune disorders to thrombosis and OAPS.

Conclusions:

• Understanding the role of the mTOR signaling pathway is crucial for comprehending APS pathogenesis.
• Targeting the mTOR pathway presents a potential new therapeutic strategy for APS.
• Further investigation into mTOR could open new avenues for APS management.